Discover more insights into Investigational Agents 조사 요원

Keywords frequently search together with Investigational Agents 조사 요원

Narrow sentence examples with built-in keyword filters

Investigational Agents sentence examples within Emerging Investigational Agents



Genomic Profiling of Circulating Tumor DNA from Patients with Extensive-Stage Small Cell Lung Cancer Identifies Potentially Actionable Alterations


Novel developments in the treatment of acute bacterial skin and skin structure infections

Investigational Agents sentence examples within Several Investigational Agents



Efficient trial designs to evaluate treatments in a public health emergency


The leukemia strikes back: a review of pathogenesis and treatment of secondary AML

Investigational Agents sentence examples within Novel Investigational Agents



Potential New Therapeutic Approaches for Myelofibrosis


Vancomycin‐resistant Enterococcus in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice



Investigational Agents sentence examples within Multiple Investigational Agents



B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy


Challenges with Novel Clinical Trial Designs: Master Protocols

Investigational Agents sentence examples within Promising Investigational Agents



Ensuring continued progress for development of COVID-19 therapeutics in children


RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.

Investigational Agents sentence examples within investigational agents targeting



Abstract CT243: A phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced renal cell carcinoma (RCC) who progressed on PD-1/L1 and VEGF inhibitors


Novel treatment modalities for painful diabetic neuropathy.


New and emerging lipid-lowering therapy.



Abstract CT243: A phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced renal cell carcinoma (RCC) who progressed on PD-1/L1 and VEGF inhibitors



ASHP national survey of pharmacy practice in hospital settings: Impact of COVID-19 pandemic on pharmacy operations-2020.



Comprehensive genomic profiling (CGP) via peripheral blood liquid biopsies identifies therapeutically relevant genomic alterations in tubo-ovarian and peritoneal cancer



Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT2): Challenges and Opportunities in Conducting an MD Anderson Randomized Study in Precision Oncology.



Novel bone microenvironment model of castration-resistant prostate cancer with chitosan fiber matrix and osteoblasts



Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms.



“Evaluating and Managing Tardive Dyskinesia in the Older Adult”



CML End Phase and Blast Crisis: Implications and Management



Role of CTSA institutes and academic medical centers in facilitating preapproval access to investigational agents and devices during the COVID-19 pandemic



Ensuring continued progress for development of COVID-19 therapeutics in children



Protocol Deviations: A Holistic Approach from Defining to Reporting



Sequential combination therapies for HBeAg-positive chronic hepatitis B: the search continues



Novel treatment modalities for painful diabetic neuropathy.



Resistance to second-generation androgen receptor antagonists in prostate cancer



Chromosome 8 gain is associated with high-grade transformation in MPNST



Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial



Declining Use of Corticosteroids for Crohn’s Disease Has Implications for Study Recruitment: Results of a Pilot Randomized Controlled Trial



The impact of the SARS-COV2 pandemic on the delivery of chemotherapy for gynecologic cancer at a tertiary care institution in the United States epicenter



A phase I/II, multicenter, open-label study of REGN5668 (mucin [MUC]16 x CD28 bispecific antibody [bsAb]) with cemiplimab (programmed death [PD]-1 Ab) or REGN4018 (MUC16 x CD3 bsAb) in recurrent ovarian cancer (rOVCA).



Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus.



A Review on Repurposed Drugs and Vaccine Trials for Combating SARS CoV-2.



Genomic Profiling of Circulating Tumor DNA from Patients with Extensive-Stage Small Cell Lung Cancer Identifies Potentially Actionable Alterations



Potential New Therapeutic Approaches for Myelofibrosis



RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.



Trends in Oral Abstracts Presented at ASTRO from 2011-2019: Radiation-Drug Combinations.



The Combination of Venetoclax and Ixazomib Selectively and Efficiently Kills HIV-Infected Cell Lines but Has Unacceptable Toxicity in Primary Cell Models



Chimeric Antigen Receptor T-Cell Therapeutics for Multiple Myeloma



Clinicogenomic characterization of metastatic thymic epithelial tumors.



Clinical trials assessing hypomethylating agents combined with other therapies: causes for failure and potential solutions.



Increased risk of immune-related hepatitis among adolescent and young adults (AYAs) with melanoma during immunotherapy with checkpoint inhibitors (ICIs).



Juggling While Dancing



Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola



Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.



B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy



Improving consent forms for first-in-human trials through participant feedback.



Efficient trial designs to evaluate treatments in a public health emergency



Prospective experimental treatment of colorectal cancer patients based on organoid drug responses



Bench to bedside radiosensitizer development strategy for newly diagnosed glioblastoma



A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC).



Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities



Pathologic Response to Neoadjuvant Therapy is Associated With Improved Long-term Survival in High-risk Primary Localized Malignant Peripheral Nerve Sheath Tumors



Liver safety assessment in clinical trials of new agents for chronic hepatitis B



Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds



Network meta‐analyses of systemic treatments for psoriasis: a critical appraisal



IgA nephropathy: un update.



Novel developments in the treatment of acute bacterial skin and skin structure infections



FDA-regulated research: cellular therapy considerations



Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer.



SAT0204 LUPUS LOW-DISEASE ACTIVITY STATE VS SLE RESPONDER INDEX IN A “REAL-LIFE” SETTING



Factor XI inhibition fulfilling the optimal expectations for ideal anticoagulation



Differential effects of NSAIDs on amyloid β1-42 peptide aggregation



Anticancer activity of a small molecule, tolfenamic acid: An emphasis on pancreatic cancer



Abstract 3719: Systemic and subcutaneous modeling of A20 murine B cell lymphoma in mice: A comparative assessment



The leukemia strikes back: a review of pathogenesis and treatment of secondary AML



Antibody-Drug Conjugate-Based Therapeutics: State of the Science.



Vancomycin‐resistant Enterococcus in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice



Canagliflozin in Type 1 Diabetes: A Case Series of Patient Outcomes in a Diabetes Clinic



Oral rimegepant increased freedom from pain and from most bothersome symptom at 2 h in acute migraine



Investigational luteinizing hormone releasing hormone (LHRH) agonists and other hormonal agents in early stage clinical trials for prostate cancer



Abstract P2-03-01: Akt inhibition associated with change in immunophenotype of tumor microenvironment (TME) in breast cancer (BC)



Focused Ultrasound Strategies for Brain Tumor Therapy.



Understanding the Right to Try Act



Decreasing the Toxicity of Radiation Therapy: Radioprotectors and Radiomitigators Being Developed by the National Cancer Institute Through Small Business Innovation Research Contracts.



Challenges with Novel Clinical Trial Designs: Master Protocols



A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects
.


Learn more from Investigational Agents 조사 요원

Investigational Agents 조사 요원


Investigational Agents 조사 요원
Encyclopedia 백과사전